The Newswire

Your daily serving of financial goodness

Israeli medical pioneer Meron eyes ASX listing with latest venture

Israeli medical pioneer Meron eyes ASX listing with latest venture
HyGIeaCare is a US based health care company, which owns and operates five medical centres across the US, offering a FDA-cleared colon cleansing method.
Sep 19, 2017 By Simon Herrmann Tags: IPO, HGC

Gavriel Meron is a pioneer in the medical device industry and he is now taking his latest venture to Australia and aims a listing on the ASX before the end of the month.

HyGIeaCare is a US based health care company, which owns and operates five medical centres across the US, offering a FDA-cleared colon cleansing method to prepare patients for colonoscopy or to provide relief from chronic constipation. The company is trying to raise up to A$15 million to be valued at A$40 million. 

In 1998 Gavriel Meron founded Given Imaging, which he led from an idea to a billion-dollar Nasdaq-listed company. As president and CEO he led the commercialisation of the ‘Pillcam’ – a disposable capsule designed to diagnose disorder of the gastrointestinal tract – before taking the company public in 2001. Before and after his tenure at GI, he held executive positions in a number of other high profile public companies.

Acting as Founder, Chairman and CEO of HyGIeaCare he aims to replicate GI’s success, facilitated by an Australian listing. HyGIeaCare was established in 2015 and has to date performed 4,450 procedures in its five centres. Two additional centres are currently under development and most of the proceeds will be used to expand the company’s footprint in the US.

In its prospectus the company lures investors with a first mover advantage, a high satisfaction rate amongst clients and the extensive network in the industry. While the IPO is highly speculative and subject to a number of risks, investing in HyGIeaCare means essentially backing up Gavriel Meron in his pursue to write another success story. 

HyGIeaCare Inc
ASX Code: HGC
CDIs on Offer: 37.5m
Listing Price: $0.40 per CDI
Market Capitalisation: $40m
Listing Date: September 25

 

Share this article

Simon Herrmann Author: Simon Herrmann Sep 19, 2017

Simon is a financial analyst at independent research firm Wise-owl specialised in small-mid cap growth opportunities and ethical investment opportunities. Simon's aim is to disrupt the cliché approach to investment decision making as he believes that socially and environmentally responsible behaviour is a necessity to long-term wealth creation. Simon has a deep fundamental understanding of the global financial landscape and has compiled 300+ research reports, valuations and corporate appraisals. Simon is commonly featured in major media outlets and his research is published weekly in The Australian.


Interested in IPOs? Bid directly here:

Loading...
Disclaimer: Clicking on this link will take you to a third-party website. We do not control or give advice regarding the content or links that appear on these sites and Wise-owl accepts no responsibility or liability in respect of any third party materials. Wise-owl may earn a commission from any product or service from third party websites.

Medical marijuana treatment for animals?

Demand for pot companies reached an all-time high in 2017 as overhyped medical marijuana companies flooded the local market, taking advantage of investor appetite for ‘the next big thing’.

Author: Simon Herrmann Oct 18, 2017

Errors

Sign Up for Free Trial
Subscribe
Recent Tweets
Recent News